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Abstract
Introduction The multifactorial etiology of septic
cardiomyopathy is not fully elucidated. Recently, high
catecholamine levels have been suggested to contribute to
impaired myocardial function.
Methods This retrospective analysis summarizes our preliminary
clinical experience with the combined use of milrinone and
enteral metoprolol therapy in 40 patients with septic shock and
cardiac depression. Patients with other causes of shock or
cardiac failure, patients with beta-blocker therapy initiated more
than 48 hours after shock onset, and patients with pre-existent
decompensated congestive heart failure were excluded. In all
study patients, beta blockers were initiated only after
stabilization of cardiovascular function (17.7 ± 15.5 hours after
shock onset or intensive care unit admission) in order to
decrease the heart rate to less than 95 beats per minute (bpm).
Hemodynamic data and laboratory parameters were extracted
from medical charts and documented before and 6, 12, 24, 48,
72, and 96 hours after the first metoprolol dosage. Adverse
cardiovascular events were documented. Descriptive statistical
methods and a linear mixed-effects model were used for
statistical analysis.
Results Heart rate control (65 to 95 bpm) was achieved in
97.5% of patients (n = 39) within 12.2 ± 12.4 hours. Heart rate,
central venous pressure, and norepinephrine, arginine
vasopressin, and milrinone dosages decreased (all P < 0.001).
Cardiac index and cardiac power index remained unchanged
whereas stroke volume index increased (P  = 0.002). In two
patients (5%), metoprolol was discontinued because of
asymptomatic bradycardia. Norepinephrine and milrinone
dosages were increased in nine (22.5%) and six (15%) patients,
respectively. pH increased (P < 0.001) whereas arterial lactate
(P  < 0.001), serum C-reactive protein (P  = 0.001), and
creatinine (P = 0.02) levels decreased during the observation
period. Twenty-eight-day mortality was 33%.
Conclusion Low doses of enteral metoprolol in combination
with phosphodiesterase inhibitors are feasible in patients with
septic shock and cardiac depression but no overt heart failure.
Future prospective controlled trials on the use of beta blockers
for septic cardiomyopathy and their influence on
proinflammatory cytokines are warranted.
Introduction
Septic cardiomyopathy refers to myocardial injury with or with-
out lowered cardiac output in patients with sepsis [1,2]. In
contrast to earlier beliefs concerning the frequency of septic
cardiomyopathy, a recent prospective trial in 67 adult septic
shock patients without previous cardiac disease reported an
overall hypokinesia rate (left ventricular ejection fraction of less
than 45%) of 60% [3]. As compared with patients able to
maintain hyperdynamic circulation, survival is significantly
compromised in septic shock patients with low systemic blood
flow [4]. Even if cardiac output can be preserved, myocardial
injury as indicated by increased plasma levels of troponin [5]
or natriuretic peptides [6-8] is associated with poor outcome
in septic shock.
AVP = arginine vasopressin; bpm = beats per minute; CI = cardiac index; CPI = cardiac power index; ICU = intensive care unit; MAP = mean arterial 
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The etiology of septic cardiomyopathy is multifactorial.
Throughout the last decades, several pathogenetic mecha-
nisms, including bacterial toxins, cytokines, nitric oxide, and
reactive oxygen species, were identified [2,9]. Recently, the
contributory role of adrenergic stress and catecholamine-
induced toxicity has been suggested [2]. Similarities have
been drawn between catecholamine-induced myocardial stun-
ning [10,11] and septic cardiomyopathy [12]. Sepsis was
found to be an important risk factor for development of the left
ventricular apical ballooning syndrome [13], originally known
as Takotsubo cardiomyopathy [14].
In view of the growing evidence for an association between
beta adrenergic stress and the pathogenesis of septic cardio-
myopathy [15], the administration of beta-blocking agents
could be beneficial. Although at first glance it appears coun-
terproductive to administer a potentially negative inotropic
drug to a patient with myocardial depression, beta-blocker
therapy improved myocardial oxygen utilization, decreased
tumor necrosis factor-alpha production, and preserved car-
diac function in a septic animal model [16]. Similarly, Gore and
Wolfe [17] found that a continuous esmolol infusion reduced
heart rate by 20% but did not compromise systemic oxygen
delivery or organ blood flow in six hemodynamically stable
patients with sepsis.
Apart from these studies, an increasing number of reports
have been published suggesting advantageous effects of beta
blockers in acute critical illness. Though recently challenged
[18,19], perioperative beta blockade has repeatedly been
shown to reduce cardiac complications and improve survival in
high-risk surgery patients [20,21]. Similarly, preliminary data
on the use of beta blockers in critically ill patients with severe
trauma [22], traumatic brain injury [23], or burns [24] indicate
a beneficial influence on morbidity and mortality.
In an effort to reduce tachycardia in patients with septic shock
requiring inotropic therapy, we have cautiously started to use
beta blockers. First, this therapeutic intervention was
restricted to patients with chronic beta-blocker therapy in
order to attenuate rebound tachycardia and decrease the risk
of perioperative myocardial ischemia but later was also used in
patients without chronic beta-blocker treatment in an attempt
to decrease high heart rate and economize cardiac function.
This retrospective analysis summarizes our preliminary clinical
experience with the combined use of milrinone and enteral
metoprolol therapy in 40 patients with septic shock and car-
diac depression. Our hypothesis was that metoprolol would
reduce heart rate without destabilizing cardiovascular
function.
Materials and methods
The retrospective protocol was approved by the Ethics Com-
mittee of the Krankenhaus der Barmherzigen Schwestern in
Ried im Innkreis. In view of the retrospective study design, writ-
ten informed consent was waived. From 1 January 2005 to 28
February 2008, all medical records of an eight-bed multidisci-
plinary intensive care unit (ICU) were reviewed for patients
with the admission diagnosis of septic shock as defined by the
American College of Chest Physicians and the Society of Crit-
ical Care Medicine [25]. All patients with septic shock and car-
diac depression who were treated with enteral metoprolol
within 48 hours after the onset of shock or admission to the
ICU were included in the analysis. Cardiac depression was
defined as a central venous oxygen saturation (ScvO2) of less
than 65% despite adequate fluid resuscitation, oxygenation,
and hematocrit, and/or a cardiac index (CI) of less than 2.5 L/
minute per m2 requiring inotropic therapy. Patients younger
than 18 years, patients with any cause of low cardiac output
other than sepsis (for example, myocardial ischemia), patients
with pre-existent decompensated congestive heart failure
(New York Heart Association classification III and IV), patients
with septic shock who did not require inotropic support or in
whom cardiac output was not measured, and patients who
first received beta blockers more than 48 hours after the onset
of shock or ICU admission were excluded.
Hemodynamic and general treatment
All septic shock patients were invasively monitored with an
arterial and a central venous catheter as well as a transpulmo-
nary thermodilution device to assess cardiac output (PICCO®;
Pulsion Medical Systems, Munich, Germany). Hemodynamic
resuscitation was performed according to an institutional pro-
tocol (Figure 1) that served as a recommendation for the
attending physician. During shock, all patients were mechani-
cally ventilated and sedated with a midazolam/fentanyl infu-
sion. Continuous veno-venous hemofiltration with a minimum
filtration rate of 35 mL/minute was commenced for renal indi-
cations only (n = 28, 70%). Nutrition was initiated via the
parenteral route on ICU day 2 and gradually substituted with
enteral nutrition starting on ICU day 3 or when cardiovascular
function was stabilized.
Beta-blocker therapy
In an effort to decrease the heart rate to less than 95 beats per
minute (bpm), compassionate use of metoprolol was started
as considered indicated by the physician in charge. First,
metoprolol was restricted to patients with chronic beta-
blocker therapy in order to attenuate rebound tachycardia and
decrease the risk of perioperative myocardial ischemia, but
after one third of the observation period was also used in
patients without chronic beta-blocker treatment in an attempt
to treat tachycardia and economize cardiac function. In all
patients, beta blockers were initiated only after cardiovascular
function had been stabilized. A retard formulation of metopro-
lol (Seloken retard®; AstraZeneca, Vienna, Austria) was used
at 25 to 47.5 mg via the enteral route. Based on response in
heart rate, stroke volume or CI, and arterial blood pressure,
metoprolol was gradually increased to reach a targeted heart
rate of 65 to 95 bpm. Metoprolol was transiently stopped orAvailable online http://ccforum.com/content/12/4/R99
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completely withdrawn if the heart rate dropped to less than 60
bpm.
Data documentation
Where available, the following variables were extracted from
routinely performed measurements documented in the medi-
cal charts: demographic data, pre-existent diseases, chronic
beta-blocker therapy, source of infection, need for renal
replacement therapy, length of stay in the ICU, and 28-day
mortality. The Simplified Acute Physiology Score II [26] and a
modified Goris multiple organ dysfunction syndrome score
[27] were calculated from most aberrant clinical and labora-
tory variables during the first 24 hours after admission or dur-
ing the ICU stay, respectively. Hemodynamic data were
documented at shock onset and before and 6, 12, 24, 48, 72,
and 96 hours after the first metoprolol dosage and included
heart rate, mean arterial blood pressure (MAP), central venous
pressure, ScvO2, CI, and stroke volume index (SVI) as well as
norepinephrine, arginine vasopressin (AVP), and milrinone
requirements. The cardiac power index (CPI), an index of car-
diac contractility strongly correlated with outcome in acute
and chronic heart failure [28], was calculated as the product
of simultaneously measured MAP and CI (CPI [W/m2] = MAP
× CI × 0.0022). Systemic vascular resistance was calculated
according to the standard formula. Also documented were the
time elapsed between shock onset and initiation of metoprolol
therapy as well as the time between initiation of metoprolol
therapy and attainment of the targeted heart rate range. Serum
concentrations of creatinine, aspartate, and alanine ami-
notransferase, total bilirubin, troponin I, C-reactive protein, and
the arterial oxygen tension/inspiratory oxygen tension (PaO2/
FiO2) quotient were recorded before and 24, 48, 72, and 96
hours after the start of metoprolol. pH and arterial lactate levels
were documented before and 6, 12, 24, 48, 72, and 96 hours
after the first metoprolol dosage.
Definition of adverse events
To evaluate the incidence of adverse events during the 96-
hour observation period, the following definitions were retro-
spectively applied. A decrease in arterial blood pressure was
considered a greater than 20% reduction in MAP as com-
pared with baseline values or an MAP of less than 65 mm Hg
at two or more time points, both requiring an increase in nore-
pinephrine support. A decrease in CI, SVI, or ScvO2 was sim-
ilarly defined as a greater than 20% reduction as compared
with baseline values at two or more time points, requiring an
increase in inotropic support and/or withdrawal of metoprolol
therapy. Bradycardia was defined as a drop in heart rate to
less than 60 bpm and was considered to be symptomatic if it
Figure 1
Institutional hemodynamic protocol Institutional hemodynamic protocol. *Fluid resuscitation using crystalloids to cover basal fluid demands (~30 mL/kg per day) and colloids for further 
fluid loading (guided by responses in stroke volume and cardiac index, arterial and central venous pressure, heart rate, and clinical signs). Colloids 
hydroxyethyl starch (molecular weight, 130.000; Voluven® 130/0.4; Fresenius Kabi, Graz, Austria) with a dose limitation of 30 mL/kg per day based 
on the manufacturer's instructions and gelatine (molecular weight, 22.600; Gelofusin®; B. Braun, Melsungen, Germany) without a dose limitation 
were used. #New-onset tachyarrhythmias, progressive tachycardia of greater than 110 beats per minute despite adequate fluid resuscitation, pulmo-
nary arterial hypertension with new signs of right heart dysfunction, new-onset hyperglycemia (blood sugar of greater than 130 mg/dL) resistant to 
insulin dosages of greater than 5 IU/hour, new increase in troponin serum concentrations, or progressive deterioration of diastolic or systolic ven-
tricular function. CI, cardiac index; MAP, mean arterial blood pressure; NE, norepinephrine; RBC, red blood cell; ScvO2, central venous oxygen 
saturation.Critical Care    Vol 12 No 4    Schmittinger et al.
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resulted in an MAP of less than 65 mm Hg or CI of less than
2.5 L/minute per m2.
Statistical analysis
The primary endpoint was to assess the clinical course and
hemodynamic parameters during combined milrinone and
metoprolol therapy. The secondary endpoint was to evaluate
changes in laboratory and organ function parameters. The
SPSS® 12.0.1. software package was used for statistical anal-
ysis (SPSS Inc., Chicago, IL, USA). Kolmogorov-Smirnov tests
were used to verify normal distribution of study variables,
which was approximately given for all variables except serum
liver enzymes and total bilirubin concentrations, as well as arte-
rial lactate levels. After ln transformation, the normality
assumption was achieved for these variables, too. Descriptive
statistical methods were applied to present demographic and
clinical data and to evaluate the incidence of adverse events.
Changes in hemodynamic or laboratory parameters during
metoprolol therapy were assessed with a linear mixed-effects
model. In contrast to conventional tests such as the analysis of
variance, this method can evaluate changes over time despite
the fact that some patients dropped out because they died
during the observation period [29]. If changes over time were
significant, comparisons versus baseline values were per-
formed using the same model and applying Bonferroni correc-
tions. P values of less than 0.05 were considered to indicate
statistical significance. All variables are given as mean value ±
standard deviation, if not indicated otherwise.
Results
During the review period, 174 patients with septic shock were
treated in the ICU. Forty of those patients were treated with a
milrinone infusion and received enteral metoprolol during the
first 48 hours after shock onset or ICU admission (17.7 ± 15.5
hours) (Table 1). Seven patients died during the observation
period. Heart rate was reduced to the targeted range of 65 to
95 bpm in 97.5% of the patients (n = 39) within 12.2 ± 12.4
hours. Of the 36 patients treated with AVP, 31 received AVP
before baseline measurements whereas 5 patients were
started on AVP therapy during the observation period (within
6 hours, n = 4; within 24 hours, n = 1). While heart rate and
central venous pressure significantly decreased, SVI
increased during the observation period. At the same time,
norepinephrine, AVP, and milrinone dosages were significantly
reduced (Table 2). A significant increase in pH as well as
decreases in arterial lactate, serum creatinine, and C-reactive
protein levels were seen during the observation period (Table
3). Metoprolol therapy was discontinued in two patients
because asymptomatic bradycardia occurred and heart rate
remained within the lower targeted limits after one and two
metoprolol dosages, respectively. The incidence of adverse
events during the observation period is presented in Table 4.
Discussion
After cardiovascular stabilization, heart rate and central
venous pressure decreased and SVI increased in this study
population during combined milrinone and enteral metoprolol
therapy. Simultaneously, vasopressor and inotropic drug sup-
port was reduced. Except for an increase in pH as well as
decreases in arterial lactate, serum creatinine, and C-reactive
protein levels, organ function variables remained unchanged.
Pathophysiologically, septic cardiomyopathy is defined as an
inadequately increased cardiac output in relation to the low-
ered systemic vascular resistance in sepsis and does not nec-
essarily imply that cardiac output is absolutely decreased
[1,2]. Indeed, overt cardiac failure as known from patients with
cardiogenic shock is rare and has been observed in a maxi-
Table 1
Characteristics of the study population
Number 40
Age, years 71 ± 13
Male gender, number (percentage) 21 (53)
Body mass index, kg/m2 28 ± 7
Premorbidities, number (percentage)
Chronic arterial hypertension 23 (58)
Obstructive coronary artery disease 10 (25)
Compensated congestive heart failure 12 (30)
Chronic obstructive pulmonary disease 8 (20)
Chronic renal insufficiency 14 (35)
Chronic liver disease 4 (10)
Neoplasm 3 (8)
Chronic beta-blocker therapy, number (percentage) 15 (38)
Source of infection, number (percentage)
Liver/Abdomen 21 (53)
Lung 10 (25)
Skin/Soft tissue 3 (8)
Joint/Bone 2 (5)
Catheter/Device 1 (3)
Urogenital tract 1 (3)
Unknown origin 2 (5)
Continuous veno-venous hemofiltration, number 
(percentage)
28 (70)
Multiple organ dysfunction syndrome score (12), points 9.9 ± 2.3
Simplified Acute Physiology Score II, points 53 ± 16
Intensive care unit length of stay, days 15 ± 11
28-day mortality, number (percentage) 13 (33)
Data are presented as mean value ± standard deviation, if not 
indicated otherwise.Available online http://ccforum.com/content/12/4/R99
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mum of 10% to 15% of septic shock patients [30]. More com-
monly, the clinical picture of septic cardiomyopathy is
characterized by a variable degree of myocardial depression
which can be detected echocardiographically or biochemi-
cally through elevated troponin levels in greater than or equal
Table 2
Hemodynamic variables at shock onset and during the observation period
ICU 
admissiona
Baseline 6 hours 12 hours 24 hours 48 hours 72 hours 96 hours P value
Patients, number 40 40 40 39 37 37 35 33
Heart rate, bpm 110 ± 19 101 ± 18 84 ± 17b 84 ± 14b 84 ± 13b 83 ± 13b 79 ± 13b 78 ± 14b <0.001c
MAP, mm Hg 59 ± 19 85 ± 23 82 ± 15 85 ± 18 87 ± 15 90 ± 20 91 ± 20 90 ± 21 0.16
CVP, mm Hg 14 ± 4 12 ± 3 12 ± 4 12 ± 3 11 ± 3 11 ± 3b 10 ± 3b 9 ± 3b <0.001c
Cardiac index, L/
minute per m2
1.9 ± 0.6 3.1 ± 1.1 3.2 ± 1.0 3.3 ± 0.9 3.4 ± 0.9 3.4 ± 1.0 3.5 ± 1.0 3.5. ± 0.8 0.56
SVI, mL/beat per m2 18 ± 7 32 ± 12 40 ± 14 40 ± 12 42 ± 12b 42 ± 13b 42 ± 10b 44 ± 9b 0.002c
CPI, W/m2 0.24 ± 0.14 0.61 ± 0.32 0.57 ± 
0.22
0.60 ± 0.17 0.65 ± 
0.18
0.68 ± 
0.30
0.71 ± 
0.25
0.68 ± 0.23 0.27
ScvO2, percentage 64 ± 12 71 ± 10 72 ± 6 72 ± 11 74 ± 9 77 ± 8 73 ± 11 72 ± 11 0.35
SVRI, dyne-second/
cm5 per m2
2,041 ± 
1,181
2,114 ± 825 1,918 ± 
897
1,913 ± 
777
1,895 ± 
647
2,014 ± 
800
2,060 ± 
852
1,824 ± 569 0.78
NE, μg/kg per minute 0.12 ± 0.25 
(n = 18)
0.17 ± 0.11 0.18 ± 
0.11
0.18 ± 0.11 0.17 ± 
0.13
0.13 ± 
0.13
0.09 ± 
0.08b
0.06 ± 0.07b <0.001c
AVP dosage, IU/hour NA 2.0 ± 1.6 2.2 ± 1.3 2.1 ± 1.3 2.1 ± 1.2 1.9 ± 1.3 1.3 ± 1.3 0.8 ± 1.1b <0.001c
Mil, μg/kg per minute 0.24 ± 0.19 
(n = 6)
0.31 ± 0.16 0.34 ± 
0.17
0.33 ± 0.16 0.30 ± 
0.17
0.24 ± 
0.18
0.21 ± 
0.19
0.12 ± 0.13b <0.001c
Meto, mg NA 47 ± 19 NA NA 47 ± 41 52 ± 42 51 ± 42 54 ± 37 NA
aNot included in the longitudinal mixed-effects analysis. bSignificant effects versus baseline. cSignificant time effect. Data are presented as mean 
value ± standard deviation. AVP, arginine vasopressin; bmp, beats per minute; CPI, cardiac power index; CVP, central venous blood pressure; 
ICU, intensive care unit; MAP, mean arterial blood pressure; Meto, metoprolol dosage; Mil, milrinone requirements (n in parentheses indicates the 
number of patients who received milrinone already at intensive care unit admission); NA, not administered; NE, norepinephrine requirements (n in 
parentheses indicates the number of patients who received norepinephrine already at intensive care unit admission); ScvO2, central venous 
oxygen saturation; SVI, stroke volume index; SVRI, systemic vascular resistance index.
Table 3
Organ function variables during the observation period
Baseline 6 hours 12 hours 24 hours 48 hours 72 hours 96 hours P value
Patients, number 40 40 39 37 37 35 33
pH 7.36 ± 0.09 7.37 ± 0.06 7.37 ± 0.1 7.38 ± 0.08 7.38 ± 0.07a 7.4 ± 0.06a 7.42 ± 0.07a <0.001b
Lactate, mg/dL 22 ± 15 24 ± 14 29 ± 32 14 ± 10a 12 ± 8a 11 ± 7a 10 ± 5a <0.001b
Creatinine, mg/dL 2.3 ± 1.3 NM NM 2.0 ± 1.0 1.8 ± 0.7 1.7 ± 0.8 1.6 ± 0.7a 0.02b
ASAT, IU/L 230 ± 651 NM NM 143 ± 253 166 ± 320 199 ± 474 153 ± 336 0.97
ALAT, IU/L 128 ± 435 NM NM 78 ± 222 90 ± 225 101 ± 207 90 ± 157 0.78
Bilirubin, mg/dL 1.7 ± 1.4 NM NM 1.6 ± 1.3 1.5 ± 1.1 1.5 ± 1.5 1.6 ± 2.2 0.60
C-reactive protein, mg/dL 17.6 ± 8.7 NM NM 17.8 ± 9.1 15.2 ± 9.3 11.6 ± 8.6 10 ± 8.2 0.001b
Troponin I, μg/L 8 ± 40 NM NM 6 ± 21 3 ± 9 3 ± 7 2 ± 5 0.60
Platelet count, 109/L 145 ± 78 NM NM 132 ± 88 130 ± 106 134 ± 112 133 ± 123 0.95
PaO2/FiO2 244 ± 129 NM NM 243 ± 92 252 ± 102 238 ± 84 262 ± 89 0.87
aSignificant effects versus baseline. bSignificant time effect. Data are presented as mean value ± standard deviation. ALAT, alanine 
aminotransferase; ASAT, aspartate aminotransferase; FiO2, inspiratory oxygen tension; NM, not measured; PaO2, arterial oxygen tension.Critical Care    Vol 12 No 4    Schmittinger et al.
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to 50% [3,31] and greater than 40% [5], respectively, of sep-
sis patients. Independently of the presence of overt cardiac
failure, the grade of myocardial depression correlates with
poor prognosis in sepsis [2,4]. In our analysis, all patients suf-
fered from septic shock with considerably impaired cardiac
pump function requiring infusion of an inotropic agent. Even
though moderately elevated troponin I serum concentrations in
92.5% of the study patients (n = 37) further underline the
presence of septic cardiomyopathy, the lack of echocardiog-
raphy data limits the detailed investigation of cardiac dysfunc-
tion in our analysis.
Despite the growing evidence that beta blockers can be safely
and probably beneficially administered in acute critical illness,
current use of beta-blocking agents in patients with septic
shock and cardiomyopathy must definitely be considered
experimental. In an attempt to reduce tachycardia in patients
with chronic beta-blocker therapy in whom rebound tachycar-
dia was suspected [32], we have initiated enteral metoprolol
therapy for the first time. The results of a study of the favorable
effects of perioperative beta blockade [33] then prompted us
to employ beta blockers in patients without previous chronic
beta-blocker therapy. Nonetheless, in all patients, this was
done compassionately and as considered indicated by the
treating physician, starting cautiously with low metoprolol dos-
ages and under tight control of cardiac output and ScvO2.
A selective beta-1, instead of a non-selective, beta blocker
was chosen to prevent inhibition of potentially beneficial beta-
2 effects [34]. Since in our clinical experience esmolol infusion
was associated with frequent and rapid decreases in heart
rate and cardiac output, metoprolol was applied via the enteral
route. Accordingly, Gore and Wolfe [17] observed a 20%
decrease in CI during esmolol infusion in hemodynamically
stable sepsis patients. Since heart rate is a major determinant
of myocardial oxygen consumption [35], it was used to dose
metoprolol. In cardiovascular high-risk patients, a heart rate of
95 bpm was shown to be the critical threshold at which myo-
cardial oxygen demand outstripped coronary supply and myo-
cardial ischemia was likely to occur [36,37].
Instead of beta-agonists, a phosphodiesterase III inhibitor was
applied as an inotropic agent in all of our patients. Although
this does not correspond to current recommendations [38],
milrinone has been used in patients with septic shock at our
institution throughout the last decade. Positive inotropic
effects of milrinone are mediated through inhibition of the
breakdown of cAMP by phosphodiesterases [39] and act
independently of beta-1 receptors. In view of differences in
cAMP-independent actions [40] and compartmentation of
cAMP-mediated signaling [41], the combination of milrinone
and metoprolol may hold potential benefits for myocardial
function [39].
A decrease in heart rate together with an increase in SVI given
an unchanged CI can be interpreted as an economization of
cardiac work and oxygen consumption. Reduced heart rates
lower the risk of myocardial ischemia [21,36,37], particularly in
patients with obstructive coronary artery disease [42]. In light
of diminishing milrinone support, these observations may even
reflect improved cardiac pump function in our study patients.
Moreover, a decrease in central venous pressure as observed
during metoprolol therapy often follows amelioration of myo-
cardial performance [28]. The observation that organ function
variables remained unchanged during beta-blocker therapy
strengthens the assumption that metoprolol therapy did not
reduce systemic blood flow or limit organ oxygen supply. Sim-
ilarly, organ blood flow (extremity and hepatic blood flow) was
not overtly affected during esmolol infusion in six hemodynam-
ically stable sepsis patients [17]. Since metoprolol therapy
was commenced 17.7 ± 15.5 hours after the onset of shock
and initiation of standard hemodynamic therapy, it is unlikely
that cardiovascular changes simply resulted from fluid therapy,
vasopressor, or milrinone infusion. However, because of the
uncontrolled design, our study cannot prove a causative rela-
tionship between the observed hemodynamic changes and
metoprolol therapy.
In view of the preference of milrinone over dobutamine and the
frequent use of a supplementary AVP infusion, the hemody-
namic effect during enteral metoprolol therapy can be inter-
preted only in the context of our institutional hemodynamic
protocol. For example, infusion of AVP in 95.6% of the study
patients could have interfered with the hemodynamic effects
of metoprolol therapy. Likewise, a decrease in heart rate as
well as a mild increase in CI was reported during supplemen-
tary AVP infusion in patients with advanced vasodilatory shock
and hypodynamic circulation [43]. Although in most patients
(89%) AVP was started before metoprolol therapy, we cannot
determine the extent to which this influenced the hemody-
namic course during the observation period.
Response to metoprolol in this study population was not
entirely homogeneous. Whereas overall MAP and CI did not
decrease, nine and seven patients exhibited a decrease in
MAP and CI, respectively, requiring an increase in
Table 4
Adverse events during the observation period
Number (percentage)
Asymptomatic bradycardia 2 (5)
Symptomatic bradycardia 0 (0)
Increase in norepinephrine dosage 9 (22.5)
Decrease in cardiac index 7 (17.5)
Decrease in cardiac index and ScvO2 1 (2.5)
Decrease in stroke volume index 2 (5)
Increase in milrinone dosage 6 (15)
ScvO2, central venous oxygen saturation.Available online http://ccforum.com/content/12/4/R99
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norepinephrine or milrinone dosages during the observation
period. It cannot be proven that the observed changes reflect
beneficial or adverse effects of metoprolol. It is conceivable
that without beta-blocker therapy SVI would have increased
even more and milrinone infusion could have been withdrawn
earlier. Similarly, the decrease in MAP and CI in some patients
may have resulted from the course of the underlying disease
process instead of being related to metoprolol therapy.
Data from experimental and clinical studies suggest that sev-
eral beta-blocker effects such as heart rate control [44], antag-
onization of catecholamine-induced stunning of the
myocardium [11,45,46], and reduction of myocardial inflam-
mation [47,48] may be beneficial in patients with septic myo-
cardial depression. Although data are still conflicting [49],
beneficial effects of beta blockers were reported to also
include attenuation of an overshooting immune response.
Adult trauma patients treated with a continuous beta-blocker
infusion exhibited lower serum interleukin-6 levels than did
controls receiving standard of care [22]. Reduced proinflam-
matory cytokine production was also illustrated during esmolol
infusion in rats with septic cardiomyopathy [16]. Interestingly,
serum C-reactive protein levels decreased during metoprolol
therapy in our study. Although it could be hypothesized that
metoprolol reduced interleukin-6 levels and thus C-reactive
protein levels [50], many other factors such as focus control
[38], adequate antibiotic therapy [38], and hemodynamic sta-
bilization [51] are likely to have caused the decrease of C-
reactive protein levels in our analysis.
In addition to the uncontrolled study design, other important
limitations need to be noted when interpreting the results of
our analysis. First, this is a retrospective study and it entails
potential difficulties because of missing values in individual
patients. Furthermore, patient enrolment was not performed
according to a strict protocol as in a prospective trial but at the
discretion of the attending physician. Therefore, some patients
who would have been eligible for metoprolol therapy accord-
ing to our treatment scheme may have been missed. Second,
although a hemodynamic protocol that served as a recommen-
dation for resuscitation of septic shock patients was available,
we cannot be sure whether the attending physicians strictly
adhered to the protocol during resuscitation of all study
patients. Third, a population of 40 patients is too small for ade-
quately evaluating the safety profile of metoprolol therapy in
patients with septic shock and cardiac depression.
Conclusion
Low doses of enteral metoprolol in combination with phos-
phodiesterase inhibitors are feasible in patients with septic
shock and cardiac depression but no overt heart failure. Future
prospective controlled trials on the use of beta blockers for
septic cardiomyopathy and their influence on proinflammatory
cytokines are warranted.
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